You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
How UnitedHealth used a questionable artery-screening program to boost payments
My colleagues’ relentless examination of the nation’s largest health insurer has turned up yet another problematic practice: Pushing clinicians to use a thinly tested medical device to screen patients for artery disease, boosting its own payments from the federal government for years. Each questionable diagnosis for peripheral artery disease netted UnitedHealth Group thousands of extra dollars for Medicare Advantage beneficiaries, and clinicians told STAT that in many cases, those diagnoses weren’t even medically useful, incurring false positives or only flagging early-stage disease that isn’t typically treated.
“The corporation views patients as entities that have money attached to their bodies,” Michael Good, a retired physician who worked at a Connecticut practice where UnitedHealth tested older patients with the screening device, called QuantaFlo, told STAT. “They want to use the clinicians to mine the money that lies within the bodies of the patient.” Read more from Casey Ross, Lizzy Lawrence, Bob Herman and Tara Bannow.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect